Study guide
5.2 Interventions That Reduce COPD Mortality & Exacerbation Management
ABIM Internal Medicine Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: The ABIM Exam, Blueprint & Study Strategy
0.1 Exam Format, Question Types & the 2026 Blueprint 0.2 Eligibility, Registration, Fees & Exam-Day Logistics 0.3 Scoring, the Passing Standard & Score Reports 0.4 Building a Blueprint-Weighted Study Plan
2 Chapter 1: Cardiovascular Disease (14% of Exam)
1.1 Ischemic Heart Disease & Acute Coronary Syndromes 1.2 Antithrombotic Therapy, Secondary Prevention & Mechanical Complications of MI 1.3 Atrial Fibrillation, Atrial Flutter & Stroke Prevention 1.4 Supraventricular Tachycardias, Ventricular Arrhythmias & Bradycardias 1.5 Heart Failure: Classification, Staging & Guideline-Directed Medical Therapy 1.6 Device Therapy, HFpEF & the Cardiomyopathies 1.7 Valvular Heart Disease & Endocarditis Prophylaxis 1.8 Pericardial Disease & Acute Aortic Syndromes 1.9 Hypertension: Classification, Diagnosis & Secondary Causes 1.10 Hypertensive Crises & Dyslipidemia 1.11 Adult Congenital Heart Disease & Coarctation of the Aorta 1.12 Syncope: Reflex, Orthostatic & Cardiac Causes 1.13 Cardiac Physical Examination, Murmurs & Antithrombotic Selection
3 Chapter 2: Endocrinology, Diabetes & Metabolism (9% of Exam)
2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy 2.2 Insulin Therapy, Hyperglycemic Emergencies & Chronic Complications 2.3 Thyroid Function Testing & Hypothyroidism 2.4 Thyrotoxicosis, Thyroid Storm & Thyroid Nodules 2.5 Adrenal & Pituitary Disorders 2.6 Hypercalcemia, Hypocalcemia & Disorders of Mineral Metabolism 2.7 Osteoporosis & Paget Disease of Bone 2.8 Ovarian, Testicular & Reproductive Endocrine Disorders 2.9 Hypoglycemia, Endocrine Tumors, Polyglandular Syndromes & Severe Hypertriglyceridemia
4 Chapter 3: Gastroenterology & Hepatology (9% of Exam)
3.1 Esophageal Disease 3.2 Stomach & Duodenal Disease and Gastrointestinal Hemorrhage 3.3 Inflammatory Bowel Disease 3.4 Celiac Disease & Irritable Bowel Syndrome 3.5 Diverticular Disease & Colorectal Cancer Screening 3.6 Viral Hepatitis, Steatotic & Alcohol-Associated Liver Disease 3.7 Cirrhosis & the Complications of Portal Hypertension 3.8 Acute Pancreatitis 3.9 Chronic Pancreatitis & Biliary Tract Disease 3.10 Inherited, Autoimmune & Drug-Induced Liver Disease 3.11 Small Intestinal Disease, Ischemia & Gastrointestinal Complications of HIV
5 Chapter 4: Infectious Disease (9% of Exam)
4.1 Lower Respiratory Tract Infections & Sepsis Syndromes 4.2 Viral Respiratory Pathogens & Tuberculosis 4.3 Central Nervous System Infections 4.4 Skin, Soft Tissue, Bone & Joint Infections 4.5 Infective Endocarditis & Cardiovascular Infection 4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection 4.7 HIV Diagnosis, Antiretroviral Therapy & Prevention 4.8 Opportunistic Infections & Sexually Transmitted Infections 4.9 Fever of Unknown Origin, Neutropenic Fever & Toxic Shock 4.10 Travel-Related Illness, Vector-Borne Disease & Outbreaks 4.11 Infection Prevention, Nosocomial Infection & Postexposure Prophylaxis 4.12 Rheumatic Fever, Poststreptococcal Disease, Enteric & Hepatic Infections
6 Chapter 5: Pulmonary Disease (9% of Exam)
5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy 5.2 Interventions That Reduce COPD Mortality & Exacerbation Management 5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus 5.4 Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis 5.5 Sarcoidosis, Hypersensitivity Pneumonitis & Occupational Lung Disease 5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation 5.7 Pulmonary Hypertension & Sleep-Disordered Breathing 5.8 Acute Respiratory Distress Syndrome & Mechanical Ventilation 5.9 Pleural Disease, Empyema & Pneumothorax 5.10 Bronchiectasis, Cystic Fibrosis & Restrictive Lung Disease 5.11 Evaluation of Cough, Dyspnea, Hemoptysis & the Solitary Pulmonary Nodule
7 Chapter 6: Rheumatology & Orthopedics (9% of Exam)
6.1 Rheumatoid Arthritis: Diagnosis & Systemic Manifestations 6.2 Antirheumatic Pharmacotherapy & the Spondyloarthropathies 6.3 Gout: Pathophysiology & Acute Management 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease 6.5 Osteoarthritis 6.6 Systemic Lupus Erythematosus 6.7 Systemic Sclerosis, Sjogren Syndrome & Inflammatory Myopathies 6.8 The Vasculitides 6.9 Regional Musculoskeletal Syndromes, Back Pain & Sports Injuries 6.10 Other Primary Rheumatic Disorders & Mixed Connective Tissue Disease 6.11 Osteonecrosis & Metabolic Bone Disease
8 Chapter 7: Hematology (6% of Exam)
7.1 Approach to Anemia & the Microcytic Anemias 7.2 Macrocytic, Normocytic & Hemolytic Anemias 7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient 7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal 7.6 Acute Leukemias, Chronic Leukemias & Myeloproliferative Neoplasms 7.7 Lymphomas & Plasma Cell Disorders 7.8 Myelodysplastic Syndrome, Myeloproliferative Neoplasms & Porphyria 7.9 Transfusion Medicine & Late Complications of Transplantation
9 Chapter 8: Medical Oncology (6% of Exam)
8.1 Breast, Lung, Colorectal & Prostate Cancer 8.2 Oncologic Emergencies 8.3 Genitourinary & Gynecologic Malignancies 8.4 Head and Neck, Bone & Soft Tissue Cancer and Cancer of Unknown Primary 8.5 Complications of Cancer & Its Treatment 8.6 Cancer Prevention, Survivorship & Psychosocial Care
10 Chapter 9: Nephrology & Urology (6% of Exam)
9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy 9.2 Glomerular Disorders & Nephrotic Syndrome 9.3 Nephritic Syndromes, RPGN & Indications for Renal Replacement Therapy 9.4 Chronic Kidney Disease: Staging & Progression Retardation 9.5 Complications of Chronic Kidney Disease: Anemia, CKD-MBD & Acidosis 9.6 Hyponatremia, Hypernatremia & Water Balance 9.7 Potassium Disorders & Systematic Acid-Base Analysis 9.8 Renal Tubular Acidosis & Nephrolithiasis 9.9 Prostate Disorders, Urinary Incontinence & Other Urologic Conditions 9.10 Cystic Kidney Disease, Obstructive Uropathy, Tubulointerstitial Disease & Hematuria
11 Chapter 10: Neurology (4% of Exam)
10.1 Acute Ischemic Stroke: Syndromes & Reperfusion 10.2 Transient Ischemic Attack, Secondary Prevention & Hemorrhagic Stroke 10.3 Headache & Facial Pain 10.4 Seizures, Epilepsy & Movement Disorders 10.5 Multiple Sclerosis & Neuromuscular Junction Disorders 10.6 Motor Neuron Disease & Acute Peripheral Neuropathy 10.7 Cranial Neuropathies & Neuro-Ophthalmology 10.8 Peripheral Neuropathies, CNS Tumors & Other Neurologic Disorders
12 Chapter 11: Psychiatry & Behavioral Health (4% of Exam)
11.1 Major Depressive Disorder & Medical Mimics 11.2 Antidepressant Pharmacotherapy & Treatment-Resistant Depression 11.3 Bipolar Disorder, Mood Stabilizers & Lithium Toxicity 11.4 Anxiety, Stress-Related & Obsessive-Compulsive Disorders 11.5 Alcohol Use Disorder & Withdrawal 11.6 Pharmacotherapy for Alcohol & Opioid Use Disorder 11.7 Toxidromes, Psychiatric Emergencies & Suicide Risk Assessment 11.8 Psychotic, Somatic Symptom, Factitious & Personality Disorders 11.9 Eating Disorders, Sleep Disorders & Sexual Health
13 Chapter 12: Dermatology (3% of Exam)
12.1 Dermatitis, Papulosquamous & Inflammatory Dermatoses 12.2 Acne, Rosacea & Cutaneous Infections 12.3 Herpes Zoster & Autoimmune Blistering Diseases 12.4 Nodules, Tumors & Cutaneous Oncology 12.5 Dermatologic Emergencies & Severe Cutaneous Adverse Reactions 12.6 Pigment Disorders, Alopecia, Nail Disease & Photosensitivity 12.7 Vascular Dermatoses, Environmental Injury & Cutaneous Signs of Systemic Disease
14 Chapter 13: Obstetrics & Gynecology / Women's Health (3% of Exam)
13.1 Contraception, Preconception Care & Teratogenicity 13.2 Hypertensive Disorders of Pregnancy & Gestational Diabetes 13.3 Thyroid Disease & Venous Thromboembolism in Pregnancy 13.4 Menopause & Menopausal Hormone Therapy 13.5 Abnormal Uterine Bleeding, Endometrial Disease & Gynecologic Cancer Screening 13.6 Breast Disorders & Diseases of the Vulva and Vagina 13.7 Menstrual Disorders, Fibroids, Endometriosis & Early Pregnancy Complications
15 Chapter 14: Geriatric Syndromes (3% of Exam)
14.1 Comprehensive Geriatric Assessment & Frailty 14.2 Falls, Gait Assessment & Polypharmacy 14.3 Urinary Incontinence & Pressure Injuries in Older Adults 14.4 Mild Cognitive Impairment, Dementia & Its Subtypes 14.5 Delirium & the Pharmacotherapy of Cognitive Disorders 14.6 Palliative Care, Hospice & Advance Care Planning 14.7 Chronic Wounds, Nutrition, Swallowing, Constipation & Hip Fracture 14.8 Sensory Impairment, Dizziness, Elder Mistreatment & Care Settings
16 Chapter 15: Allergy & Immunology (2% of Exam)
15.1 Anaphylaxis: Recognition & Emergency Management 15.2 Urticaria & Angioedema 15.3 Drug Allergy, Desensitization & Adult Immunodeficiency 15.4 Food Allergy, Insect Venom Hypersensitivity, Serum Sickness & Contrast Reactions 15.5 Rhinitis, Conjunctivitis, Eosinophilic & Mast Cell Disorders
17 Chapter 16: Preventive Medicine, Immunization & Clinical Epidemiology
16.1 The USPSTF Framework & Evidence-Based Cancer Screening 16.2 Cardiovascular & Metabolic Screening and Primary Prevention 16.3 Adult Immunization & Vaccines in Special Populations 16.4 Clinical Epidemiology, Biostatistics & Study Design
18 Chapter 17: Miscellaneous - Ethics, Patient Safety & Quality Improvement (2% of Exam)
17.1 Principles of Bioethics & Decisional Capacity 17.2 Informed Consent, Treatment Refusal & Special Scenarios 17.3 Surrogate Decision-Making, Advance Directives & Confidentiality 17.4 Patient Safety Science, Medical Error & Diagnostic Reasoning 17.5 Quality Improvement Methods, Health Disparities & Health Equity
19 Chapter 18: Perioperative Medicine & Medical Consultation
18.1 Preoperative Cardiovascular Risk Assessment 18.2 Preoperative Pulmonary Risk & Perioperative Medication Management 18.3 Perioperative Anticoagulation, Bridging & Postoperative Complications
20 Chapter 19: Ophthalmology (1% of Exam)
19.1 The Acute Red Eye & Ophthalmic Emergencies 19.2 Painless Vision Loss & Chronic Ophthalmic Disease 19.3 Uveitis, Scleritis & Orbital Disease
21 Chapter 20: Otolaryngology & Dental Medicine (1% of Exam)
20.1 Dizziness, Vertigo & Epistaxis 20.2 Ear Disorders, Hearing Loss & Upper Respiratory Infections 20.3 Oral Cavity, Salivary Gland, Laryngeal & Taste and Smell Disorders
5.2 Interventions That Reduce COPD Mortality & Exacerbation Management
Key Takeaways Explain This Topic AI
Smoking cessation and long-term oxygen therapy for qualifying hypoxemia are the interventions with the strongest mortality benefit in COPD.
Long-term oxygen therapy improves survival only when resting arterial oxygen tension is at or below 55 mmHg, or at or below 59 mmHg with cor pulmonale or erythrocytosis.
Pulmonary rehabilitation improves symptoms, exercise capacity and quality of life and reduces rehospitalization after an exacerbation.
Short courses of systemic corticosteroids are as effective as prolonged courses in exacerbations and cause fewer adverse effects.
Non-invasive positive pressure ventilation reduces intubation and mortality in exacerbations with hypercapnic acidosis.
Last updated: August 2026
1. Evidence-Based Interventions That Reduce Mortality in COPD
On the ABIM exam, you must distinguish interventions that improve symptoms/reduce exacerbations from those proven to reduce all-cause mortality .
Intervention Evidence / Clinical Trial Basis Specific Patient Population / Indication
Smoking Cessation Lung Health Study (LHS): Slows the accelerated rate of FEV1 decline toward normal age-related loss (~30 mL/yr vs ~60 mL/yr) and significantly reduces all-cause and cardiovascular mortality. All active smokers with COPD. Combine pharmacotherapy (Varenicline, Bupropion, or Nicotine Replacement Therapy) with behavioral counseling.
Supplemental Long-Term Oxygen Therapy (LTOT) NOTT (Nocturnal Oxygen Therapy Trial) & MRC Trials: Improves survival, reduces secondary polycythemia, decreases pulmonary arterial pressure, and improves neurocognitive function when worn >= 15 hours/day (continuous 24 hours/day provides greatest benefit). Indicated when resting room-air arterial blood gas shows:; 1. PaO2 <= 55 mmHg (or SaO2 <= 88% ); OR; 2. PaO2 56–59 mmHg (or SaO2 89% ) in the presence of cor pulmonale , clinical right heart failure (peripheral edema), or secondary polycythemia (Hematocrit > 55%) .
Lung Volume Reduction Surgery (LVRS) NETT (National Emphysema Treatment Trial): Resection of 20–30% of hyperinflated, non-functional lung tissue via bilateral video-assisted thoracoscopic surgery (VATS) reduces dynamic hyperinflation and improves diaphragmatic excursion and survival. Patients with bilateral upper-lobe predominant emphysema AND low post-rehabilitation exercise capacity (post-rehab maximal workload <=40W for men, <=25W for women).; (Contraindicated if FEV1 <=20% with homogeneous emphysema or DLCO <=20%).
Non-Invasive Positive Pressure Ventilation (NIV) in AECOPD Multiple randomized controlled trials: Reduces intubation rate by ~65% and in-hospital mortality by ~50% in acute hypercapnic respiratory failure. Patients presenting with acute hypercapnic respiratory acidosis (pH < 7.35 and PaCO2 > 45 mmHg) during an acute COPD exacerbation.
Preventive Vaccinations CDC / ACIP & GOLD recommendations: Decreases serious lower respiratory tract infections and hospitalizations. PCV20 (or PCV15 followed by PPSV23 >=1 year later), annual Influenza , COVID-19 , RSV vaccine (single dose for adults >=60 years), and Tdap (pertussis booster).
Exam Pearl: Inhaled medications (LABAs, LAMAs, ICS) improve quality of life, reduce exacerbation rates, and increase FEV1, but have not been definitively proven to independently reduce all-cause mortality as monotherapies in large survival trials (e.g., TORCH trial), although triple therapy (IMPACT, ETHOS trials) demonstrated reduced mortality compared to dual therapy in selected high-risk exacerbators.
2. Acute Exacerbation of COPD (AECOPD) Management
An acute exacerbation is defined as an event characterized by dyspnea and/or cough and sputum that worsens over <=14 days, often triggered by respiratory viral infections (rhinovirus, influenza, RSV) or bacterial pathogens ( Haemophilus influenzae , Streptococcus pneumoniae , Moraxella catarrhalis , and Pseudomonas aeruginosa in severe obstruction).
Inpatient Pharmacotherapy Protocol
Inhaled Bronchodilators: Short-acting beta-2 agonist (Albuterol 2.5–5 mg) plus short-acting muscarinic antagonist (Ipratropium 0.5 mg) via nebulizer or MDI with spacer every 1–4 hours as needed.
Systemic Corticosteroids: Oral Prednisone 40 mg daily for exactly 5 days (supported by the landmark REDUCE trial , which proved 5 days is non-inferior to 14 days regarding re-exacerbation and mortality, while significantly decreasing cumulative steroid adverse effects and hospital length of stay). IV methylprednisolone is reserved for patients unable to tolerate oral intake.
Antibiotic Therapy (5–7 Days Duration):
Anthonisen Criteria Indications: Antibiotics are indicated if the patient has all 3 cardinal symptoms (Type 1: increased dyspnea + increased sputum volume + increased sputum purulence) OR 2 cardinal symptoms if one is increased sputum purulence (Type 2), OR any patient requiring mechanical ventilation (invasive or non-invasive) .
First-Line Oral Agents: Azithromycin (500 mg day 1, then 250 mg daily days 2–5), Doxycycline (100 mg BID), or Amoxicillin-Clavulanate (875/125 mg BID).
Pseudomonas Risk Factors: FEV1 < 30% predicted, recent hospitalization (>=2 days in past 90 days), frequent antibiotic courses (>=4 in past year), or prior Pseudomonas isolation. If present, treat with Levofloxacin (750 mg daily), Ciprofloxacin (500–750 mg BID), or IV Cefepime/Piperacillin-Tazobactam.
Ventilatory Support: Non-Invasive Positive Pressure Ventilation (NIV / BiPAP)
Definitive Indications: Acute hypercapnic respiratory acidosis defined by arterial pH < 7.35 and PaCO2 > 45 mmHg despite initial medical therapy, or severe dyspnea with signs of respiratory muscle fatigue (use of accessory muscles, paradoxical abdominal motion).
Initial Settings: Bilevel PAP (BiPAP) in spontaneous/timed mode: Inspiratory Positive Airway Pressure (IPAP) 10–12 cm H2O, Expiratory Positive Airway Pressure (EPAP) 4–5 cm H2O, titrated to achieve tidal volumes of 6–8 mL/kg and relieve dyspnea. Target arterial pH > 7.35 and PaO2 >= 60 mmHg (SaO2 88–92%).
Absolute / Relative Contraindications to NIV (Mandates Immediate Endotracheal Intubation):
- Respiratory arrest or gasping respirations
- Severe hemodynamic instability (shock, refractory ventricular arrhythmias)
- Inability to protect airway, impaired consciousness / coma (GCS < 8), or uncooperative patient
- Massive upper GI bleeding, intractable vomiting, or high aspiration risk
- Severe facial trauma, burns, or anatomical abnormalities preventing mask seal